ACR Juvenile Idiopathic Arthritis — Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis and Systemic JIA Guideline Pocket Guide - Guideline Central
Key Points
Treatment
logo_primary_text

Juvenile Idiopathic Arthritis — Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis and Systemic JIA

American College of Rheumatology


Publication Date: March 3, 2022

Quality of Evidence and Strength of Recommendations

Quality of EvidenceInterpretation
High-quality evidenceStudies that provide high confidence in the effect estimate. New data from future studies are thought unlikely to change the effect.
Moderate-quality evidenceStudies that provide confidence that the true effect is likely to be close to the estimate but could be substantially different.
Low-quality evidenceStudies that provide limited confidence about the effect. The true effect may be substantially different from the estimate.
Very low-quality evidenceStudies that provide very little certainty about the effect. The true effect may be quite different from the estimate.
Strength of RecommendationInterpretation
Strong recommendationAction should be favored in almost all patients, usually requiring high-quality evidence, high confidence that future research will not alter the conclusion, AND an assessment that the desirable effects of the intervention outweigh the undesirable effects. Should not be taken to imply that the intervention has large clinical benefits.
Conditional recommendationAction should be followed in only selected cases, often limited by low-quality evidence, OR when the desirable and undesirable consequences of an intervention are more balanced, OR if patients’ preferences for the intervention are thought to vary widely.

Abbreviations

DMARD
disease-modifying antirheumatic drug(s)
GC
glucocorticoid(s)
HCQ
hydroxychloroquine
IAGCs
intra-articular glucocorticoids
IL
interleukin
JAK
janus kinase
JIA
juvenille idiopathic arthritis
LEF
leflunomide
MAS
macrophage activation syndrome
MTX
methotrexate
NSAID
non-steroidal anti-inflammatory drug
OBRM
other biologic response modifiers
SSZ
sulfasalazine
THA
triamcinolone hexacetonid
TMJ
temporomandibular joint
TNFi
tumor necrosis factor-alpha inhibitors

Source Citation

Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis (JIA): Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint (TMJ) Arthritis and Systemic JIA

Disclaimer

This pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.